LIFECORE BIOMEDICAL, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
LIFECORE BIOMEDICAL, INC. (LFCR) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$1.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-08-05
- LIFECORE BIOMEDICAL, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-06-30 was -$1.20M.
- LIFECORE BIOMEDICAL, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-03-31 was -$3.15M.
- LIFECORE BIOMEDICAL, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-09-30 was -$375.00K.
- LIFECORE BIOMEDICAL, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-05-25 was -$1.09M.
- LIFECORE BIOMEDICAL, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2025 was $409.00K, a 98.96% decline from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was $39.50M.
- LIFECORE BIOMEDICAL, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was $0.00.
- LIFECORE BIOMEDICAL, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2022 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 1 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 7 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.20M 10-Q · filed 2026-08-05 | -$4.36M 10-Q · filed 2026-08-05 | ||||
| 2026-03-31 | -$3.15M 10-Q · filed 2026-05-06 | |||||
| 2025-12-31 | -$1.57M 10-KT · filed 2026-03-16 | |||||
| 2025-09-30 | -$375.00K 10-Q · filed 2025-11-06 | |||||
| 2025-06-30 | -$125.00K 10-KT · filed 2026-03-16 | |||||
| 2025-05-25 | -$1.09M 10-Q · filed 2026-08-05 | -$1.69M 10-Q · filed 2026-08-05 | -$491.00K derived: sum of 3 quarters · filed 2026-08-05 | $409.00K 10-KT · filed 2026-03-16 | ||
| 2025-02-23 | -$600.00K 10-Q · filed 2026-05-06 | $600.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.50M 10-Q · filed 2025-04-03 | -$900.00K derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $1.90M 10-KT · filed 2026-03-16 | |||||
| 2024-11-24 | $1.20M 10-Q · filed 2025-01-02 | $2.10M 10-Q · filed 2025-01-02 | -$300.00K derived: sum of 3 quarters · filed 2026-03-16 | $20.70M derived: sum of 4 quarters · filed 2026-03-16 | ||
| 2024-08-25 | $900.00K 10-Q · filed 2025-11-06 | -$1.50M derived: sum of 2 quarters · filed 2026-03-16 | $19.50M derived: sum of 3 quarters · filed 2026-03-16 | $40.20M derived: sum of 4 quarters · filed 2026-03-16 | ||
| 2024-05-26 | -$2.40M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $18.60M derived: sum of 2 quarters · filed 2026-03-16 | $39.30M derived: sum of 3 quarters · filed 2026-03-16 | $39.50M 10-KT · filed 2026-03-16 | ||
| 2024-02-25 | $21.00M 10-Q · filed 2025-04-03 | $41.70M derived: sum of 2 quarters · filed 2025-04-03 | $41.90M 10-Q · filed 2025-04-03 | $41.90M derived: sum of 4 quarters · filed 2025-04-03 | ||
| 2023-11-26 | $20.70M 10-Q · filed 2025-01-02 | $20.90M 10-Q · filed 2025-01-02 | $20.90M derived: sum of 3 quarters · filed 2025-01-02 | $20.90M derived: sum of 4 quarters · filed 2025-01-02 | ||
| 2023-08-27 | $200.00K 10-Q · filed 2024-10-04 | $200.00K derived: sum of 2 quarters · filed 2024-10-04 | $200.00K derived: sum of 3 quarters · filed 2024-10-04 | $200.00K derived: sum of 4 quarters · filed 2024-10-04 | ||
| 2023-05-28 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-26 | $0.00 derived: sum of 2 quarters · filed 2024-08-26 | $0.00 derived: sum of 3 quarters · filed 2024-08-26 | $0.00 10-K · filed 2024-08-26 | ||
| 2023-02-26 | $0.00 10-Q · filed 2024-08-09 | $0.00 derived: sum of 2 quarters · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | |||
| 2022-11-27 | $0.00 10-Q · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | ||||
| 2022-08-28 | $0.00 10-Q · filed 2024-08-09 | |||||
| 2022-05-29 | $0.00 10-K · filed 2024-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |